Is Akarti Therapeutics PLC (ADR) (AKTX) A Good Stock To Buy?

We already know that not all hedge funds are bullish on the stock and some hedge funds actually sold off their positions entirely. At the top of the heap, Oleg Nodelman’s EcoR1 Capital sold off the largest stake of the “upper crust” of funds monitored by Insider Monkey, totaling close to $0.9 million in stock, and Nathan Fischel’s DAFNA Capital Management was right behind this move, as the fund sold off about $0 million worth of shares.

Let’s check out hedge fund activity in other stocks – not necessarily in the same industry as Akarti Therapeutics PLC (ADR) (NASDAQ:AKTX) but similarly valued. We will take a look at Cherokee Inc. (NASDAQ:CHKE), Fate Therapeutics Inc (NASDAQ:FATE), PC Tel Inc (NASDAQ:PCTI), and Tremor Video Inc (NYSE:TRMR). This group of stocks’ market caps resemble AKTX’s market cap.

As you can see these stocks had an average of 4.5 hedge funds with bullish positions and the average amount invested in these stocks was $20 million. That figure was $19 million in AKTX’s case. Cherokee Inc. (NASDAQ:CHKE) is the most popular stock in this table. On the other hand Tremor Video Inc (NYSE:TRMR) is the least popular one with only 3 bullish hedge fund positions. Compared to these stocks Akarti Therapeutics PLC (ADR) (NASDAQ:AKTX) is more popular among hedge funds. Considering that hedge funds are fond of this stock in relation to its market cap peers, it may be a good idea to analyze it in detail and potentially include it in your portfolio.

Disclosure: None